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Oscar Alzate1,2,4*, Cristina Osorio1, Robert M DeKroon1, Ana Corcimaru1 and Harsha P Gunawardena3Abstract
Introduction: Alzheimer’s disease (AD) is the major cause of dementia among the elderly. Finding blood-based
biomarkers for disease diagnosis and prognosis is urgently needed.
Methods: We studied protein distributions in brain tissues, cerebrospinal fluid (CSF), and blood of AD patients by
using proteomics and a new proteomic method that we call “2D multiplexed Western blot” (2D mxWd). This
method allows us to determine in multiple samples the electrophoretic patterns of protein isoforms with different
isoelectric points.
Results: Apolipoprotein E (ApoE) displays a unique distribution of electrophoretic isoforms in the presence of AD
and also a unique pattern specific to the APOE genotype.
Conclusions: The isoelectric distribution of differentially charged ApoE isoforms was used to determine the
presence of AD in a small group of samples. Further studies are needed to validate their use as predictors of
disease onset and progression, and as biomarkers for determining the efficacy of therapeutic treatments.Introduction
More than 5.4 million people have Alzheimer’s disease
(AD) in the United States, and it has been calculated
that, by the year 2050, 11 to 16 million Americans will
have the disease [1]. Characterizing the AD-specific
proteome and its dynamics will increase our under-
standing of the initiation and the progression of this
disease, potentially allowing the development of specific-
ally targeted treatments and strategies to prevent its on-
set. When AD is found in patients younger than 60 to
65 years of age, it is usually referred as “early-onset famil-
ial AD” (EOFAD). These cases represent only an esti-
mated 5% of all AD cases. Most AD cases occur after 60
to 65 years of age (identified as “late-onset AD”, or
LOAD). The gene APOE, encoding the lipid-carrier pro-
tein apolipoprotein E (ApoE), has been established as a
risk factor of developing LOAD [2-7].* Correspondence: alzate@medicine.tamhsc.edu
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unless otherwise stated.ApoE has three polymorphic variants (ApoE2, ApoE3,
and ApoE4) and is involved in several metabolic func-
tions, including lipid transport [8,9]. In the search for
blood-based biomarkers of AD with the capacity to dis-
tinguish AD from non-AD patients and also to distin-
guish the different APOE genotypes, we first investigated
which proteins vary in the hippocampus of AD patients
as a function of APOE genotype and AD status (that is,
diseased versus nondiseased).
Our findings led us to investigate differential protein
expression in the cerebrospinal fluid (CSF) of the same
AD patients. Our results demonstrated charge-based
changes in specific ApoE isoforms rather than changes
in the expression level of the ApoE protein. We there-
fore developed a method to determine the expression
patterns of these differentially charged protein isoforms
in the blood of AD patients.
We demonstrate here that, in principle, differentially
charged isoforms of ApoE from human blood may be
used to distinguish AD patients from non-AD control
subjects. This is a very important finding, because most
of the AD biomarkers currently in use (such as the
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blood is substantially easier to process, and its acquisi-
tion is less invasive.
Some of the biomarkers currently in use involve an
extensive list of molecules such as cortisol, pancreatic
polypeptide, insulin-like growth factor-binding protein 2,
microglobulin, vascular cell adhesion molecule 1, carci-
noembryonic antigen, matrix metalloproteinase 2, CD40,
macrophage inflammatory protein 1α, superoxide dis-
mutase, homocysteine, ApoE, epidermal growth factor
receptor, calcium, zinc, and interleukin 17 [18]. When
using gender, APOE genotype, and age as biomarkers,
provided a specificity of 77% in the diagnosis of AD, and
including some of the previous biomarkers, the specifi-
city improved to 84% [18]. We predicted the correct AD
status in 16 of 18 plasma samples (~89%) with just
one molecule, with the advantage that our observation
can also be used to determine the APOE genotype of
the patient providing the sample. It is important to
indicate that when the results are analyzed according
the APOE genotype, just the AD state of all of the
APOE 3/3 samples was diagnosed correctly, whereas
only 50% of the APOE 4/4 was diagnosed correctly.
This observation suggests the need for a larger sample
population to be used as a reference panel, and indi-
cates that our approach satisfies the diagnosis of the
APOE 3/3 samples.
Methods
General overview of the methodology
Informed consent from the patients and/or their care
providers for using the samples described in this study
was obtained by the Bryan Alzheimer’s Disease Research
Center (BADRC) of Duke University Medical Center,
the Knight ADRC (KADRC) of Washington University
School of Medicine in St. Louis (MO), and the Instituto
Neurologico de Colombia (Colombian Neurological In-
stitute, INDEC). Samples from AD patients are indicated
with the letter D, while non-AD samples are indicated
with the letter N. Samples from APOE3/3 or APOE4/4
diseased subjects are indicated 33D and 44D, respect-
ively; non-AD APOE3/3 samples are indicated 33 N
(Figure 1).
The general method is summarized in Figure 1. (A)
Hippocampi from AD patients and from non-AD con-
trol subjects were analyzed to determine differential
protein-expression levels. From this analysis, we found
sets of proteins unique to each disease state and unique
to each APOE genotype. (B) The latter was also observed
in the panels of proteins that displayed differential protein
expression in the patient’s CSF compared with matched
controls; (C) from the distribution of CSF proteins, it was
found that for some proteins there were changes in the
distributions of differentially charged protein isoforms.Therefore, the distribution of differentially-charged iso-
forms in the blood of AD patients was analyzed by
using the method shown in Figure 2, which is explained
in detail under section Two-dimensional multiplexed
Western blotting (2D mxWb). (D) A general pattern
for the differentially charged isoform distribution of
ApoE was then sought in the blood of AD patients
compared with age- and sex-matched controls. (E) the
distribution of charge-isoforms of ApoE was determined
in a “blind” group of unknown blood samples from
several patients for whom no information was pro-
vided. (F) The distribution patterns of ApoE charge-
isoforms from the unknown subjects were compared with
the ApoE distribution patterns from the known AD pa-
tients; and (G) the matching of the charge-state distribu-
tion to the reference patterns was used to predict the
disease state of the unknown samples.
Sample procurement, protein extraction, and quantitation
from CSF of deceased AD patients
Sample procurement, protein isolation, and proteomic
analysis of human brain tissues have been previously re-
ported [19]. CSF from deceased AD patients was acquired
by the Kathleen Price Bryan Brain Bank of the BADRC, by
following regulations of the Duke University Medical
Center, as previously described [20], and was provided to
us as de-identified samples (IRB exemption 6878-05-
1R0ER, from Duke University Health System). These sam-
ples were centrifuged at 14,000 rpm to remove particulates,
and the supernatant was filtered with a 20-μm filter. The
CSF samples were prefractionated to enrich low-abundance
proteins by removing high-abundance proteins by using
the Multiple Affinity Removal System (MARS; Agilent
Technologies, Wilmington, DE, USA), an antibody-based
100-mm affinity column, by following the manufacturer’s
instructions. CSF (30 µL) was mixed with 120 μl of buffer A
and injected into the column at a flow rate of 0.5 ml/min,
by using the auto-sampler included with the 1100
Multidimensional Liquid Chromatography (MDLC) sys-
tem (Agilent Technologies). The flow-through, contain-
ing the low-abundance proteins, was collected, and the
high-abundance proteins that remained bound to the
column were eluted with buffer B at a flow rate of 1 ml/min
(buffers A and B are proprietary buffers included with
the MARS depletion kit, and their composition is not
disclosed by the manufacturer).
Proteins fractionated by affinity chromatography were
reconcentrated with Agilent concentrator spin columns
(5 kDa MWCO, 4 ml). Purified proteins were prepared
as previously described [19,21]. Each de-identified sample,
from patients whose ages were between 78 and 85 years,
was classified only according to age, sex, APOE genotype
(3/3 versus 4/4), and cognitive status (demented (D) versus
nondemented (N)).
Figure 1 Experimental design. (A) Brain tissues from AD patients and non-AD control subjects were analyzed to determine differential protein
expression. Three groups (non-AD, APOE 3/3 (33 N), AD APOE 3/3 (33D), and AD APOE 4/4 (44D)) were compared to each other. (B) A similar
analysis was performed in the CSF samples of the same patients; (C) human blood serum from AD patients (D, APOE genotype-independent)
and non-AD control subjects (N) were analyzed to investigate the distribution of protein isoforms of several proteins, including ApoA-1, ApoE,
ApoH, and ApoJ. (D) The distribution of differentially charged protein isoforms of ApoE was analyzed in the blood of AD patients compared
with non-AD control subjects by using the recombinant human ApoE protein as reference to determine charge-isoform distribution and migration
patterns. (E) Similar experiments were carried out on a group of de-identified samples with unknown disease status. (F) The pattern of isoelectric
distribution of the unknown subjects was compared with the reference panel developed in E. (G) The distribution of ApoE charge-isoforms was
used as reference to predict the disease states and the APOE genotypes of the unknown samples.
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preparation from blood serum of AD patients
An additional group of samples used in the present
study was obtained from a larger sample group previ-
ously used to study the correlation between type 2 dia-
betes mellitus and AD in the province of Antioquia,
Colombia [22]. The samples were randomly selected
from a group of 20 samples, all of which had been deter-
mined to be homozygous for APOE3 [22]. The samples
were collected by following norms and regulations ap-
proved by the ethics committees of the INDEC and the
Universidad Pontificia Bolivariana (approved by the UPB
research committee, 21/10/2010, as described in [22]).
Because the methods used for this analysis involved
working with human biologic specimens (that is, bloodserum), an IRB exemption was filed and approved by the
Office of Human Research Ethics of the University of
North Carolina at Chapel Hill. The researchers involved
in the present study received de-identified samples that
were matched only by age and gender, and character-
ized as being from AD patients or from non-AD control
subjects.
The selected samples were from six individuals (n = 6)
who met the DSM-IVR (Diagnostic and Statistical Manual
of Mental Disorders, 4th edition, American Psychiatric
Association) criteria for AD diagnosis, and six control sub-
jects who did not meet any DSM-IVR criteria for AD [22].
All AD patients were 65 years of age or older, with no
relatives with an AD diagnosis or any type of dementia,
and had no medical history of Parkinson disease, stroke,
Figure 2 Multiplexed 2D Western blot (2D mxWb) method. (A) Proteins from several samples are separated simultaneously with isoelectric
focusing. (B) The strips are then successively loaded onto a polyacrylamide gel. The first strip is run for about 10 to 20 minutes; after this time,
this strip is removed, the gel surface is rinsed with diiH2O, and the next strip is loaded and run for another 10 to 20 minutes; after this time, the
procedure is repeated with the next strip until all of the strips are successively loaded in the SDS gel. (C) When all the strips have been run, the
proteins are transferred onto a PVDF membrane and probed with specific antibodies. For the detection of ApoE, we used anti-goat ApoE antibody
(CalBiochem) as the primary Ab and donkey anti-goat IgG-HRP as the secondary Ab.
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other conditions that could invalidate the diagnosis of
AD [22]. The control group consisted of individuals
older than 65 years of age of both genders, without a
medical history of dementia syndrome or any other neuro-
degenerative disease. The individuals were matched by sex
and age between the experimental and control groups.
Serum (40 μl) was aliquoted from each of the sam-
ples for protein purification. Sample clean-up used a
chloroform-methanol extraction procedure [23], per-
formed by mixing the serum sample with a 3:4:1 vol/vol
mixture of diiH2O, chilled methanol, and chloroform, and
centrifuged for 15 minutes at 13,500 rpm. The sampleswere then suspended in lysis buffer [19,21], and the protein
concentration of each sample was determined by using
a BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Protein quality was determined
by 1D Western blot for all samples.
Sample procurement and protein preparation from blood
samples of patients with unknown AD diagnosis
Eighteen blood plasma samples, each containing 100 to
200 μl, from AD and control patients of the KADRC,
were provided to us completely de-identified; the ethics
committee of the KADRC, Washington University, ap-
proved all the methods involved in sample collection,
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were provided to us de-identified, an IRB exception was
approved by the University of North Carolina. These sam-
ples were prepared as indicated earlier, and 10 μg of total
protein from each sample was used for 2D multiplexed
Western blotting (2D mxWb), as explained later.
Cy-dye labeling and 2D gel electrophoresis for differential
protein expression analysis
Differential protein expression in CSF from deceased AD
patients and non-AD matched controls was determined
by 2D Difference Gel Electrophoresis (2D DIGE), com-
paring all samples and determining protein-expression
differences that correlated with APOE genotype and dis-
ease state [19,24]. Samples from 33D and 44D patients
were used as the experimental groups and were com-
pared with the 33 N control group. An internal control
was created by pooling equal amounts of protein from
all of the samples. This internal control was labeled with
Cy2 and was applied to each gel, as previously described
[19,24]. 2D DIGE was performed and analyzed, as previ-
ously described [21].
Analysis of differential protein expression from CSF samples
The statistical significance of differences in protein ex-
pression was determined with GE Healthcare DeCyder
2D 7.0 software, as described [21], based on the Student
t test by using P < 0.05 as threshold. Separate tests were
performed comparing 33 N with 33D, 33 N with 44D,
and 33D with 44D. The variability of the data and the
Principal Component Analysis (PCA) were determined
with DeCyder Extended Data Analysis (EDA) module
[25]. The samples were compared as follows: (a) 33 N,
containing six “non-AD” samples, all APOE3/3 genotype;
(b) 33D, containing six “AD” patients, all genotype
APOE3/3; and (c) 44D, containing six “AD” patients, all
APOE4/4 genotype. PCA plots of each spot map were
based on the expression profile of the selected proteins.
Protein identification by mass spectrometry
Spots showing significant (P < 0.05) differential expres-
sion were excised from the gels, digested with trypsin
[26], and identified by using MS and MS/MS on an
Applied Biosystems AB 4800 MALDI TOF/TOF mass
spectrometer at the Proteomics Center of the University of
North Carolina at Chapel Hill, as previously described [27].
The proteins were identified by using the in-house GPS
Explorer Mascot database [28].
Two-dimensional multiplexed Western blotting
We developed this approach to determine variability
in protein isoform distributions. Protein posttransla-
tional modifications (PTMs) indicate addition, subtraction,
and/or modifications of functional groups [29,30]. It iscommonly found that such modifications alter the pro-
tein’s isoelectric point, the molecular weight, or both,
making 2D gel electrophoresis an efficient method for
analyzing PTMs [31]. Changes in the isoelectric point
result in protein isoforms with different charges. The
procedure for 2D mxWb is shown in Figure 2. Proteins
from multiple samples were simultaneously separated
by isoelectric focusing, as explained previously [19,31],
by using one strip per sample (Figure 2A). For the ex-
periments described here, we used an Ettan IPGphor II
(GE Healthcare) with a capacity of up to 12 strips. After
protein separation by isoelectric focusing, the strips from
each sample are successively loaded onto a polyacryl-
amide gel to run the second dimension (Figure 2B). The
first strip is run for approximately 20 minutes; after this
time, this strip is removed, the gel surface is rinsed with
diiH2O, and a second strip is loaded and run for another
20 minutes. The total number of strips that can be run in
a single 2D PAGE gel depends on several variables, in-
cluding (a) the apparent molecular weight of the target
protein, (b) the size and the density of the gel, and (c) the
potential difference used to displace the proteins. To de-
termine specific changes in a protein’s pI distribution,
we used human recombinant ApoE protein (hr-ApoE;
Fitzgerald Industries International, Acton, MS, USA; cat.
30R-AA016) as a reference. This protein is separated by
IEF along with the other strips, and is loaded on the poly-
acrylamide gel by using the same procedures as for the
target proteins.
After running the second dimension, proteins are
transferred to a PVDF membrane, and the proteins are
probed with specific antibodies (Figure 2C). For detection
of ApoE, ApoE-goat Ab (CalBiochem, La Jolla, CA, USA;
cat. 178479) was used as the primary Ab, and donkey
anti-goat IgG-HRP (Santa Cruz Biotechnology; cat. SC-
2020) was used as the secondary Ab. From the Western
blot analysis, it is possible to determine the migration
patterns of the charge-isoforms for multiple samples in a
single experiment.
LC-MS/MS-based quantitative analysis of ApoE
Solubilized protein samples from human brain tissue
were separated with 1D SDS (12%) PAGE electrophor-
esis with pre-cast gels (Bio-Rad, Hercules, CA, USA).
The apparent protein molecular weight was deter-
mined with “Kaleidoscope” prestained protein standards
(Bio-Rad). Gel strips for each sample were excised from
the Coomassie-stained gel, and each gel strip was cut into
1 × 1-mm gel pieces and transferred into Axygen 1.7-ml
tubes. Manual “in-gel” protein digestion was done as previ-
ously explained [26].
Extracted peptides were desalted by using PepClean C18
spin columns (Pierce, Rockford, IL, USA), used according
to the manufacturer’s instructions, and resuspended in an
Table 1 Human CSF proteins displaying differential expression in AD patients
Spot number Protein name/Protein ID/Uniprot Accession
Number/RefSeq
33 N versus
33D
33 N versus
44D
N versus D Molecular
weight
pI
429 Serum albumin, Chain A; ALBU_HUMAN
P02768/NP_000468.1
−1.29 −1.37 −1.33 69,366.68 5.92
P = 0.00034
541 Transferrin variant; Q53H26_HUMAN
Q53H26 /IP|00022463
−1.53 −1.50 −1.51 77,079.85 6.68
P = 0.0011
575 alpha 1-B glycoprotein; A1BG_HUMAN
P04217/NP_570602.2
−1.22 −1.18 −1.20 54,272.56 5.58
P = 0.0013
579 alpha 1-B glycoprotein; A1BG_HUMAN
P04217/NP_570602.2
−1.31 −1.31 −1.31 54,272.56 5.56
P = 0.0015
614 Transferrin variant; Q53H26_HUMAN
Q53H26/IP|00022463
+1.70 +1.64 +1.67 770,79.85 7.04
P = 0.0024
990 Apolipoprotein H (beta-2-glycoprotein I)
APOH_HUMAN P02749/NP_000033.2
+1.67 +1.60 +1.63 38,298.16 8.34
P = 0.0021
1000 Tubulin beta-2A chain; TBB2A_HUMAN
Q13885/NP_001060.1
+1.29 +1.73 +1.51 49,906.67 4.78
P = 0.0058
1008 Keratin, type II cytoskeletal 1; K2C1_HUMAN
P04264/NP_006112.3
+2.94 +2.62 +2.77 66,038.73 8.15
P = 0.002
1017 alpha-1-antitrypsin (SerpinA1); A1AT_HUMAN
P01009/NP_000286.3
+1.86 +2.26 +2.06P = 0.0021 46,739.55 5.37
1118 Pigment epithelium-derived factor (SerpinF1);
PEDF_HUMAN P36955/NP_002606.3
+1.54 +1.99 +1.77 46,342.30 5.97
P = 7.4E-05
1188 ALB protein (growth-inhibiting protein 20),
Isoform 2; ALBU_HUMAN P02768/NP_000468.1
+1.26 +1.23 +1.24 47,360.49 5.97
P = 0.0065
1268 Glutamine synthetase; GLNA_HUMAN;
P15104/NP_001028216.1
−1.38 −1.55 −1.46 42,064.46 6.43
P = 0.0025
1278 Creatine kinase B-type; KCRB_HUMAN;
P12277/NP_001814.2
−1.46 −1.40 −1.43 42,644.28 5.34
P = 0.0077
1324 Fructose-bisphosphate aldolase A; ALDOA_HUMAN
P04075/NP_000025.1
−1.49 −1.53 −1.51 39,420.02 8.30
P = 0.0074
1332 Aspartate aminotransferase, cytoplasmic;
AATC_HUMAN; P17174/NP_002070.1
−1.28 −1.49 −1.38 46,247.51 6.53
P = 0.0099
1363 Aspartate aminotransferase, cytoplasmic;
AATC_HUMAN; P17174/NP_002070.1
−1.27 −1.41 −1.33 46,247.51 6.50
P = 0.0003
1451 Glyceraldehyde-3-phosphate dehydrogenase
G3P_HUMAN P04406/NP_002037.2
−2.05 −1.75 −1.87 36,042.22 8.57
P = 0.0002
1454 Glyceraldehyde-3-phosphate dehydrogenase
G3P_HUMAN P04406/NP_002037.2
−1.45 −1.42 −1.44 36,042.22 8.59
P = 0.013
1469 Glyceraldehyde-3-phosphate dehydrogenase
G3P_HUMAN P04406/NP_002037.2
−1.58 −1.52 −1.55 36,042.22 8.63
P = 0.00094
1470 Glyceraldehyde-3-phosphate dehydrogenase
G3P_HUMAN P04406/NP_002037.2
−1.80 −1.72 −1.75 36,042.22 8.67
P = 0.0005
1472 Clusterin; Apolipoprotein J; Complement-associated
protein SP-40; CLUS_HUMAN; P10909/NP_001164609.1
+2.01 +2.01 +2.01 50,062.56 5.89
P = 5.10E-05
1521 Apolipoprotein E4; APOE_HUMAN
P02649/NP_000032.1
+2.14 +3.34 +2.74 36,154.08 5.65
P = 0.00023
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Table 1 Human CSF proteins displaying differential expression in AD patients (Continued)
1523 Clusterin; Apolipoprotein J; Complement associated
protein SP-40; CLUS_HUMAN; P10909/NP_001164609.1
+1.78 +2.17 +1.97 50,062.56 5.89
P = 3.50E-06
1527 Apolipoprotein E4; APOE_HUMAN P02649/
NP_000032.1
+2.02 +2.42 +2.22 36,154.08 5.65
P = 1.30E-05
1535 Complement component 4A; C4A; Q5JNX2_HUMAN;
Q5JNX2/IP|00643525
+1.85 +1.94 +1.89 ~3,5000 6.43
P = 7.10E-05
1554 Transthyretin; TTHY_HUMAN; P02766/NP_000362.1 +2.05 +2.58 +2.32 15,887.03 5.52
P = 0.00078
1779 Ig Kappa chain C region; IGKC; IGKC_HUMAN;
P01834/IP|00909649
−1.98 −2.14 −2.06 11,608.86 5.58
P = 0.0061
1845 Prostaglandin-H2 D-isomerase; cerebrin-28;
PTGDS_HUMAN; P41222/NP_000945.3
+1.45 +1.51 +1.48 21,028.82 7.66
P = 0.0077
1912 Apolipoprotein A-1; ApoA1; APOA1-HUMAN;
P02647/NP_000030.1
−1.78 −1.84 −1.81 30,777.83 5.56
P = 0.0037
1982 Superoxide dismutase [Mn], mitochondrial;
SODM_HUMAN; P04179/NP_000627.2
+1.66 +1.62 +1.64 24,722.09 8.35
P = 0.0011
2067 Apolipoprotein A-1; ApoA1; APOA1-HUMAN;
P02647/NP_000030.1
−1.95 −2.09 −2.02 30,777.83 5.56
P = 7.40E-06
2068 Apolipoprotein A-1; ApoA1; APOA1-HUMAN;
P02647/NP_000030.1
−2.25 −2.24 −2.24 30,777.83 5.56
P = 0.00035
The spot number is assigned by default by the DeCyder 2D 7.0 software, and is indicated on the gel image (Figure 3B). The protein name and the protein ID are
obtained from the protein database maintained at the Protein Information Resource server, Georgetown University [37].
The Uniprot accession number and the RefSeq number are protein identifiers retrieved from the Uniprot database based on the protein identification achieved by
using mass spectrometry data [38]. Changes in protein expression are expressed as the log of the ratios between the corresponding spots’ volumes, and are
automatically calculated with DeCyder 2D.
The protein’s isoelectric point (pI) and molecular weight (Mw) are associated with the protein ID in PIR [37].
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teins was done by using reversed-phase LC-MS/MS on a
2D-nanoLC Ultra system (Eksigent Inc., Dublin, CA, USA)
coupled to an LTQ-Orbitrap Velos mass spectrometer
(Thermo Scientific, San Jose, CA, USA). The Eksigent sys-
tem was configured to trap and elute peptides via an injec-
tion of ~250 fM sample. The trapping was performed on a
3 cm-long 100 μm i.d. C18 column, whereas elution was
performed on a 15 cm-long 75 μm i.d., 5 μm, 300 Å par-
ticle ProteoPep II integraFrit C18 column (New Objective
Inc, Woburn, MA, USA). Analytic separation of the tryptic
peptides was achieved with a 70-minute linear gradient of
2% to 10% buffer B at a 200 nl/min. Buffer A is an aqueous
solution of 0.1% formic acid, and buffer B is a solution of
0.1% formic acid in acetonitrile.
Mass spectrometric data acquisition was performed in a
data-dependent manner on a hybrid LTQ-Orbitrap mass
spectrometer. A full-scan mass analysis on an Orbitrap
(externally calibrated to a mass accuracy of <1 ppm,
and a resolution of 60,000 at m/z 400) was followed by
intensity-dependent MS/MS of the 10 most abundant
peptide ions. Collision-induced dissociation (CID)-MS/
MS was used to dissociate peptides with a normalizedcollision energy of 35 eV, in the presence of He bath gas
at a pressure of 1 mTorr. The MS/MS acquisition of each
precursor m/z was repeated for 30 seconds and subse-
quently excluded for 60 seconds. Monoisotopic precursor
ion selection (MIPS) and charge-state screening were en-
abled for triggering data-dependent MS/MS scans. Mass
spectra were processed, and peptide identification was
performed by using Mascot ver. 2.3 (Matrix Science Inc.)
implemented on Proteome Discoverer ver 1.3 software
(Thermo-Fisher Scientific). All searches were performed
against a curated Human data base [32]. Peptides were
identified by using a target-decoy approach with a false
discovery rate (FDR) of 1% [33]. A precursor ion mass
tolerance of 200 ppm and a product ion mass tolerance
0.5 Da were used, with a maximum of two missed tryptic
cleavages [34]. Methionine oxidation was selected as a
variable modification.
Spectral counting was performed on the Mascot DAT
files by using ProteoIQ: ver 2.3.02 (NuSep Inc., Athens,
GA, USA). Proteins identified with LC-MS/MS were
subjected to “probability-based” confidence measure-
ments by using an independent implementation of the
statistical models Peptide and Protein Prophet deployed
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probability of 0.5 and a Mascot identity with a significant
score cut-off greater than 26. Identified proteins were an-
alyzed for potential posttranslational modifications.
Results
Proteomic analysis of CSF shows that pI distributions are
altered in AD patients as a function of the APOE genotype
One hundred thirty-one spots were differentially expressed
in at least one comparison as follows: 15 in the 33N versus
33D comparison; 37 in 33N versus 44D; 21 in 33D versus
44D; and 58 in N versus D (see Additional file 1). Based
on spot size and intensity, 40 of these spots contained a
sufficient amount of protein to be identified with MS. InFigure 3 Representative 2D DIGE gel of CSF proteins and PCA of brai
control subjects were compared, with control samples labeled with Cy3 (Gree
significant different expression levels, which were successfully identified with
assigned by the DeCyder 2D software. (C) PCA analysis of all the protein
controls indicates that these are distinct experimental groups.total, 32 of the 40 spots were successfully identified
(Table 1, Figure 3B, and Additional file 1). Protein spots
541 and 614 are pI variants (that is, charge-isoforms) of
transferrin variant protein (PIR: Q53H26); spots 575 and
579 are pI variants of α1-B glycoprotein (PIR: P04217);
spots 1332 and 1363 correspond to pI variants of aspar-
tate aminotransferase (PIR: P17174); spots 1451, 1454,
1469, and 1470 represent pI variants of glyceraldehyde-3-
phosphate dehydrogenase (PIR: P04406); spot numbers
1472 and 1523 are charge-isoforms of apolipoprotein J
(also known as clusterin (PIR: P10909)); spots 1521 and
1527 are pI variants of ApoE4 (PIR: P02649); and spots
1912, 2067, and 2068 are pI variants of apolipoprotein
A-1 (PIR: P02647). Changes in the expression levels ofn proteins. (A) Low-abundance proteins from CSF of AD patients and
n) and AD samples labeled with Cy5 (Red). (B) Protein spots displaying
mass spectrometry, are shown with the spot numbers automatically
s detected from brain tissues of AD patients and corresponding
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that other charged isoforms of these proteins may be
present, in addition to those indicated here, but these
were not selected, as they did not show changes in
protein-expression levels.
Charge-based distribution of differentially charged ApoE
isoforms distinguishes AD from non-AD samples
Analysis of hippocampus from AD patients indicates
that (a) the sets of proteins characterizing the diseased
state and the APOE genotype of the AD patients repre-
sent distinctive experimental groups (PCA analysis,
Figure 3C); (b) charge-isoforms of certain proteins can
be differentially expressed without overall changes toFigure 4 Detection of ApoE charge-isoforms and prediction of AD. (A
hippocampus of AD patients and control subjects shows that the charge-is
the spot at pI = 5.8 is more abundant in the E33 group; and the non-AD pop
levels. (B) Analysis of the ApoE charge-isoforms in the serum of AD patien
(indicated by the arrows). (C) The specific features of ApoE charge-isoform
individual sample: the red arrow at the bottom indicates a feature (spot) tha
on the left indicate features that are found in groups containing at least one ε
(“smear”) that has been found only in 44D samples. The green circle shows a
groups of six unknown samples and one reference protein, indicated as hr-Apthe expression level of the whole protein [19]; (c) a pI
variant of ApoE at pH 5.2 is found in the brains of
APOE4/4 diseased patients and not found in APOE
3/3 AD or in the non-diseased controls (Figure 4A); and
(d) the ApoE charge-isoform distribution in the non-AD
controls is different from the distribution found in the
sample from subjects with AD. This is a significant obser-
vation about the ApoE charge-isoform distribution in the
human brain, but is, unfortunately, of low value for clin-
ical biomarker research, considering that these are brain
tissues. However, further analysis examining human
blood from patients with diagnoses of AD (Figure 4B)
shows that observations in hippocampal specimens are
closely mirrored in the blood of the AD patients, which) 2D mxWb analysis of the distribution of ApoE charge-isoforms in the
oform corresponding to a pI = 5.2 is unique to the 44D group; similarly,
ulation displays fewer ApoE charge-isoforms and with lower expression
ts shows that their migration patterns are unique to each population
migration patterns are used to determine the disease state of each
t is uniquely found in patients having an ε4 gene. The yellow arrows
3 along with one ε4, whereas the red circle shows a protein modification
feature that is unique to the 33D group. Each experiment was run in
oE.
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forms found only in AD patients, and not in the non-AD
controls (Red arrows in Figure 4B point out spots that are
unique to each sample). These observations were con-
firmed in six controls and six AD patients, resulting in a
distinctive pI distribution that is summarized in Figure 4B.
Plasma ApoE charge-isoform distribution may be able to
predict AD
To determine the ability of our isoelectric isoform-
distribution panel to predict AD, we performed 2D mxWb
analysis of 18 de-identified samples (Figure 4C). The re-
sults of this analysis are shown in Table 2, which demon-
strates that we were able to predict accurately the AD state
in 16 of the 18 samples (88.9%), with only two of the sam-
ples, both of the APOE4/4 genotype, not predicting the
diagnosis. The latter could be explained because we did
not have any ApoE ε4/4 samples in our reference panel for
comparison; the possibility also exists that our prediction
was correct, but dementia was not yet apparent clinically.
Discussion
We analyzed the patterns of differential protein expres-
sion in the brains of AD patients, and we found thatTable 2 Prediction of disease state by using the panel of
ApoE charge-isoforms
Sample
number
APOE
genotype
Disease state
from clinic
Disease state
predicted
1 3/4 No dementia No disease
2 3/4 No dementia No disease
3 3/4 No dementia No disease
4 3/3 No dementia No disease
5 3/3 No dementia No disease
6 3/3 No dementia No disease
7 3/3 Dementia Disease
8 3/3 Dementia Disease
9 NR Dementia Disease
10 3/3 No dementia No disease
11 4/4 No dementia Diseasea
12 4/4 No dementia Diseasea
13 4/4 Dementia Disease
14 3/4 Dementia Disease
15 4/4 Dementia Disease
16 3/4 Dementia Disease
17 3/4 Dementia Disease
18 3/4 Dementia Disease
Age range, 62.8 to 81.5 years; gender distribution, eight men, 10 women. The
APOE genotype of the patients was unknown when the experiments were
performed. NR, not reported.
aincorrectly predicted.several proteins, including mortalin, display differential
expression of individual isoforms, but not of the whole
protein (that is, the single protein resulting from the
sum of all the isoforms as detected by 1D Western blot)
[19]. This observation was confirmed and extended when
proteomic analysis of the CSF from the same patients was
performed.
Among the most interesting findings of the CSF ana-
lysis was that some differentially charged protein iso-
forms of ApoA-1, ApoE, ApoJ, and ApoH are differentially
expressed. This observation prompted the question: is it
possible that diseases and biologic processes leave a trace
of their causes and effects in the charge-isoform distribu-
tion pattern? To explore this observation further, we per-
formed analysis of the charged isoforms of ApoJ, ApoH,
ApoA-1, and ApoE in the blood of AD patients, compared
with age- and sex-matched controls. Analysis of the ApoE
charge-isoform distributions was sufficient to indicate that
a distribution is unique to the diseased population com-
pared with the control population, and that the charge-
isoform distribution also carries sufficient information
to determine the APOE genotype of the corresponding
patients.
To test the validity of our results, we requested com-
pletely de-identified samples from the Knight Alzhei-
mer’s Disease Research Center (Washington University,
St. Louis, MO, USA). By using the distribution pattern
of the charge-isoforms of ApoE, we determined the cor-
rect AD status in 16 of the 18 samples. We also were
able to determine correctly the APOE genotype of the
patients.
Additional analysis of ApoE charge-isoforms was sought
by using quantitative proteomics based on spectral count-
ing [39,40]. This procedure confirmed our previous obser-
vations [19] that the total amount of ApoE does not
display changes, contrary to variations in expression of in-
dividual charge-isoforms. Despite extensive analysis, our
MS procedures failed to determine the nature of the ApoE
modifications that may be responsible for these variations
in isoelectric focusing; however, not knowing the nature of
the modifications does not diminish our claim that the
charge-isoform distribution could be a biomarker for AD.
As extensively demonstrated in this report, what distin-
guishes AD from non-AD samples is the distribution of
the isoforms in an isoelectric analysis, not the nature of the
modifications.
The results presented here have notable advantages
over current biomarkers used by others in the scientific
community: (a) these observations are made on human
blood; (b) we target only one molecule for analysis in-
stead of tens of compounds, which should make the
diagnostic assays faster and less expensive; (c) these
results can be implemented on high-throughput plat-
forms either by optimizing our approach, implementing
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using antibodies specific for the different ApoE charge-
isoforms, or by developing fluorescent dyes specific for
each of the unique charge-isoforms, (d) the methods
presented here can be carried out in less than 4 hours
and cost less than $200, making this approach a viable
method for the diagnosis of this and other diseases,
and (e) the use of bioinformatics to develop pattern-
recognition software for analysis of charge-isoform dis-
tributions associated with diseases and different biologic
states should provide a great opportunity for diagnosis
and prognosis, and for determining disease initiation
and progression.
Conclusions
We report here the use of ApoE charge-isoforms as a
method to determine the presence of AD in blood ex-
tracts. Our method is simple, requires little sample (less
than 40 μl of blood plasma), and can be carried out in
less than a day, without requiring the presence of the pa-
tient or expensive and sophisticated equipment. As indi-
cated in our data, diagnosis from APOE 3/3 patients can
be made with high accuracy. Further studies should in-
clude significant numbers of APOE 4/4 and APOE 2/2
samples to create a robust reference panel applicable to
any APOE genotype. Studies are also needed to validate
these markers for the determination of the onset and the
progression of the disease, as well as the effectiveness of
therapeutic treatments.
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